What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cardiology
- Atrial fibrillation
Internal medicine, Cardiology, Atrial fibrillation, Stroke and Anesthesia are his primary areas of study.
Internal medicine is closely attributed to Surgery in his work.
His Atrial fibrillation research incorporates elements of Randomized controlled trial and Risk factor.
Stefan H. Hohnloser has researched Stroke in several fields, including Embolism, Catheter ablation, Clopidogrel, Aspirin and Apixaban.
His Apixaban study also includes fields such as
- Relative risk reduction and related Cystatin C,
- Edoxaban together with HAS-BLED and Management of atrial fibrillation.
Stefan H. Hohnloser has included themes like Anticoagulant, Sotalol and Amiodarone in his Anesthesia study.
His most cited work include:
- Apixaban versus Warfarin in Patients with Atrial Fibrillation (5705 citations)
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (3899 citations)
- Apixaban in Patients with Atrial Fibrillation (1891 citations)
What are the main themes of his work throughout his whole career to date?
Stefan H. Hohnloser mainly investigates Internal medicine, Cardiology, Atrial fibrillation, Anesthesia and Stroke.
In general Internal medicine, his work in Heart failure, Implantable cardioverter-defibrillator, Hazard ratio and Sinus rhythm is often linked to In patient linking many areas of study.
The study of Cardiology is intertwined with the study of Randomized controlled trial in a number of ways.
His work in Anesthesia covers topics such as Electrocardiography which are related to areas like Heart rate.
Stefan H. Hohnloser combines subjects such as Aspirin, Asymptomatic and Embolism with his study of Stroke.
His Warfarin study combines topics from a wide range of disciplines, such as Clopidogrel, Surgery and Renal function.
He most often published in these fields:
- Internal medicine (79.24%)
- Cardiology (74.45%)
- Atrial fibrillation (47.70%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (79.24%)
- Atrial fibrillation (47.70%)
- Cardiology (74.45%)
In recent papers he was focusing on the following fields of study:
Stefan H. Hohnloser mostly deals with Internal medicine, Atrial fibrillation, Cardiology, Warfarin and Dabigatran.
His study deals with a combination of Internal medicine and In patient.
His Atrial fibrillation research is multidisciplinary, incorporating perspectives in Stroke and Randomized controlled trial.
Cardioversion is closely connected to Embolism in his research, which is encompassed under the umbrella topic of Stroke.
His research on Cardiology often connects related topics like Aspirin.
The study incorporates disciplines such as Creatinine, Surgery and Renal function in addition to Warfarin.
Between 2015 and 2021, his most popular works were:
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (3899 citations)
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. (653 citations)
- Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT (232 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
